Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly acquires AME for stock and cash

Executive Summary

To power up its biotech effort, Lilly has agreed to acquire Applied Molecular Evolution (technology for optimizing large molecules) for about $400mm. AME stockowners will receive $18 for each outstanding share (a 48% premium), and they may elect to take it in cash or stock (number of shares to be based on Lilly's market price when the deal closes), with the stipulation that 80% of the total payment must be in stock.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies